Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference
December 07, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference
November 28, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...
Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update
November 14, 2022 16:05 ET
|
Onconova Therapeutics, Inc.
Initiation of Phase 1/2a endometrial cancer trial expected in 1Q23; preliminary data expected 4Q23 Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa., Nov. 14, 2022 (GLOBE...
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022
November 07, 2022 16:05 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics to Present at the Ladenburg Thalmann 2022 Healthcare Conference
September 22, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Announces Updated Data from Investigator-sponsored Phase 1/2a Trial Evaluating Rigosertib in Combination with Nivolumab in Advanced KRAS-mutated Non-Small Cell Lung Cancer at the ESMO Congress 2022
September 12, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
Data show an early signal of efficacy in an extensively pre-treated population with 1 complete response and 2 partial responses achieved in 14 evaluable patientsResponses achieved in patients with 3...
Onconova Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 01, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
August 11, 2022 16:05 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022
August 04, 2022 16:05 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Announces Key Management Promotions
June 13, 2022 08:00 ET
|
Onconova Therapeutics, Inc.
Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer Dr. Adar Makovski Silverstein promoted to Senior Director and Head of Corporate Development NEWTOWN, Pa., June 13, 2022 ...